Businessweek Daily
Plus: Korean companies add baby bonuses
View in browser
Bloomberg

This morning, the Justice Department opened up a criminal investigation into Federal Reserve Governor Lisa Cook, which is likely to cause even more rancor between the White House and the central bank. US economy reporter Matthew Boesler takes a look at the big picture. Plus: A corporate spending spree on children and another possible use for GLP-1 drugs.

If this email was forwarded to you, click here to sign up.

The Federal Reserve’s highly anticipated September policy meeting is less than two weeks away, and at this point, it’s not entirely clear who all will be in attendance.

Fed Governor Lisa Cook, whom President Donald Trump is trying to fire, is locked in a legal battle with the administration. Whether she can stay in her post while it plays out in court likely won’t be decided before the end of the week.

Meanwhile, Republicans are aiming to confirm Stephen Miran, the White House economist whom Trump nominated to temporarily fill a separate position at the Fed, in time to take part in the Sept. 16-17 interest-rate decision. Miran’s testimony on Thursday before the Senate Banking Committee quickly became explosive as Democratic Senator Elizabeth Warren pressed him on whether Joe Biden won the 2020 election and whether he agreed with Trump’s claims that the Bureau of Labor Statistics rigged labor-market data to make the president look bad.

Miran, during his Senate Banking Committee confirmation hearing in Washington on Thursday. Photographer: Daniel Heuer/Bloomberg

Regardless of how the next few days play out on either of those fronts, it’s hard to imagine the conversation around the table at the Eccles Building. Fed officials love to say politics doesn’t come up in their meetings, where they are always squarely focused on the best course of action for the American people based on an objective analysis of the latest economic data.

But consider this: Aside from the drama unfolding around Cook in federal court and Miran on Capitol Hill, Treasury Secretary Scott Bessent is also reportedly ramping up interviews with candidates to replace Fed Chair Jerome Powell when his term at the helm of the central bank ends in May.

Of the 11 candidates said to be on Bessent’s list, four—Fed vice chairs Philip Jefferson and Michelle Bowman, Fed Governor Christopher Waller and Dallas Fed President Lorie Logan—are already on the rate-setting Federal Open Market Committee.

That means come the September meeting, if a judge rules in Cook’s favor and Miran makes it through the Senate, at least six people around the FOMC table may be more or less directly engaged with the administration to varying degrees.

It’s an extraordinary setup given the backdrop, in which the whole debate over what to do with interest rates essentially hinges on how much inflation Trump’s tariff policies will create this year.

Waller, whom Trump appointed to the Fed in his first term, said last week that he would likely support a quarter-point rate cut, with the caveat that bad numbers in a monthly jobs report due Friday could tilt him toward arguing for a bigger reduction.

Miran may already be planning to make the case for a half-point move, in line with what Trump has been arguing for some time.

On the other side, there are Fed officials—notably, presidents of regional reserve banks absent from the list of names the administration is considering for the top job—who have questioned the need for a rate cut at all, given the inflation risk.

Trump’s move to fire Cook last week reportedly sparked a round of worried phone calls between the reserve bank chiefs as a once unthinkable scenario of a Trump-appointed majority on the Fed’s Board of Governors, which could in turn remove the regional officials from their positions, suddenly came into view.

Investors don’t seem too perturbed about the prospects for increased politicization of US monetary policy, even as it throws into doubt what conventional wisdom has always held up as the bedrock of global financial stability.

They could be betting on Cook’s legal team to prevail, a scenario in which the Fed’s independence would live to fight another day. But either way, Trump will have put an absolutely indelible stamp on at least one FOMC meeting, in September 2025.

Follow live: Miran’s Senate confirmation hearing

Related: Trump’s Housing Chief Wants to Build, But With What?

In Brief

Baby Bonuses at Work

A rooftop play area at Krafton’s daycare center in Seoul. Photographer: Tim Franco for Bloomberg Businessweek

It was February 2024, and the cavernous auditorium at Booyoung Co.’s Seoul headquarters was packed with hundreds of employees listening to their founder deliver what’s typically a solemn New Year’s address. But this time, Lee Joong-keun, the 84-year-old billionaire behind one of South Korea’s biggest construction companies, dropped a bombshell: Booyoung would begin offering 100 million won ($72,000) for every baby born to an employee. And, he added, the offer applied retroactively to the past three years. The room went silent for a beat, as if everyone had misheard. Then came the applause.

“I was speechless,” says Hong Ki, a 37-year-old communications manager who at the time had a 3-year-old daughter. “It was so absurd that I couldn’t even sleep, wondering if it was for real.” It was. So after Hong and his wife, who also works at Booyoung, processed the news, they did what many would do when offered a potentially life-altering pile of cash to expand their family: They had another child.

South Korea’s fertility rate is just 0.75 births per woman, the lowest on Earth, with the population projected to shrink by almost a third by 2072 if today’s pace continues. The implications are severe: a dwindling workforce, falling tax revenue, empty schools, an aging society with no one to care for the elderly, and a military facing a recruitment crisis. The government has poured hundreds of billions of dollars into the problem, from its own cash stipends for babies to subsidized housing and tax credits, with limited success. Now companies, fearing a future with no workers (and keen to attract talent at the same time), have joined in the spending spree.

Hyonhee Shin writes about the private effort to expand families: Korean Companies Pay Employees Huge Sums to Have More Kids

GLP-1s Offer Hope for Alzheimer’s Treatment

Illustration: Hoi Chan for Bloomberg Businessweek

A team of scientists was crunching Danish health registry data several years ago when it noticed something surprising: Diabetes patients who’d used Novo Nordisk A/S’s last-generation diabetes medicine Victoza or similar GLP-1 drugs appeared to be getting dementia at noticeably lower rates than those treating their diabetes another way. Specifically, adults who’d been taking the injectable for two years had about a 20% lower risk of a dementia diagnosis. “That is in and of itself not proof,” says Martin Holst Lange, the drugmaker’s chief scientific officer. But “it did catch our attention.” Novo was already looking into whether its newer GLP-1 drugs could help patients with obesity-adjacent disorders of the heart, liver and joints. Spurred in part by the analysis of the curious Danish data (which Novo helped publish), it decided to test the drugs’ effects on Alzheimer’s disease as well.

Those trial results are due out this fall, and if they show what the company hopes they do, GLP-1s could revolutionize the treatment of Alzheimer’s, the most common form of dementia. It’s in no way a sure thing, but if it works, the payoff could be huge. Analysts at UBS Group AG estimate a 1 in 10 chance that the company is able to generate an additional $15 billion in annual sales for Alzheimer’s treatment. “We are excited about this,” Novo’s Lange says. “We also see it as very, very high risk.”

Naomi Kresge writes that the drugmaker is scheduled to present data from its pair of studies of semaglutide in more than 3,500 people with mild Alzheimer’s disease at a conference in San Diego in early DecemberNovo Has High Hopes That Ozempic Pill Can Also Fight Dementia

Luxury Travel

$40,000
That’s how much the average client couple is spending annually on two weeklong vacations with CIRE Travel, according to the travel agency’s founder. That kind of money is inspiring former high-flying finance professionals to join the rapidly swelling ranks of travel advisers.

Implant Problems

“You’re supposed to trust your doctor.”
Mary Munney Griffiths
Retired administrative assistant
Searing pain, pus-filled infections and dying tissue: The BioZorb device was marketed to help breast cancer patients, but the company kept complaints from regulators and the public. Read the full story here.

More From Bloomberg

Like Businessweek Daily? Check out these newsletters:

  • Markets Daily has what’s happening in stocks, bonds, currencies and commodities right now
  • Supply Lines follows the trade wars, tariff threats and logistics shocks that are upending business and spreading volatility
  • FOIA Files goes behind the scenes with Jason Leopold to uncover documents that have never been seen before
  • Management & Work analyzes trends in leadership, company culture and the art of career building
  • Bloomberg Pursuits is your weekly guide to the best in travel, eating, drinking, fashion, driving and living well

Explore all Bloomberg newsletters.

Follow Us

Like getting this newsletter? Subscribe to Bloomberg.com for unlimited access to trusted, data-driven journalism and subscriber-only insights.

Want to sponsor this newsletter? Get in touch here.

You received this message because you are subscribed to Bloomberg's Businessweek Daily newsletter. If a friend forwarded you this message, sign up here to get it in your inbox.
Unsubscribe
Bloomberg.com
Contact Us
Bloomberg L.P.
731 Lexington Avenue,
New York, NY 10022
Ads Powered By Liveintent Ad Choices